INSP Presents New OSA Data at SLEEP 2026, Reinforcing Clinical Momentum

What happened

Inspire Medical showcased new data at SLEEP 2026, including results from the Inspire V system and the PREDICTOR study, which aim to validate broader OSA therapy adoption and improve patient selection. The company also highlighted remote patient management tools, potentially enhancing post-implant care and adherence. While these updates support the clinical rationale for Inspire therapy, the fundamental headwinds from GLP-1 competition and DOJ scrutiny remain unresolved. The data do not alter the near-term revenue trajectory, which still depends on Inspire V rollout and 2026 Medicare reimbursement tailwinds. Investors should view this as incremental positive for the bull case, but not a catalyst that shifts the balanced risk/reward.

Implication

Sustained clinical evidence for Inspire V and remote monitoring could underpin procedure growth and payer confidence, bolstering the bull case of mid-teens revenue growth and margin expansion. However, the thesis still hinges on volume execution and competitive dynamics, not just data readouts.

Thesis delta

The SLEEP 2026 data incrementally support the bull case by strengthening the clinical evidence for Inspire V and patient management tools, but they do not resolve the core uncertainties around GLP-1 cannibalization or commercial execution. The fundamental thesis remains balanced between a $70 bear case and a $150 bull case, with the base at $120. No material delta to the investment thesis; the call remains a high-conviction POTENTIAL BUY with a wide range of outcomes.